Moreover, hyperactive EGFR signaling drives MOB1 tyrosine phosphorylation to inhibit LATS1/2, thereby promoting YAP nuclear accumulation and induction of resistance-related genes; combined inhibition of EGFR and YAP signaling synergistically attenuates tumor growth and reverses therapeutic resistance (Fu et al., 2022). This evidence concerns the gene EGFR and neoplasm.